₹1,533.9
▼ -14.56 -0.94%
17 Jul 2026
NSE Listed
Aurobindo Pharma Ltd. (AUROPHARMA)
Volume: 9,24,372Avg Vol 1W: 7,33,504.6Avg Vol 1M: 15,06,457.9552W Range:₹1,016.1₹1,636.8
Key Ratios
Checked 5h agoMarket Cap₹89,931 Cr
Current Price₹1,533.9
Previous Close₹1,548.46
High / Low (52w)₹1,636.8 / ₹1,016.1
Volume9,24,372
Avg Vol (1W)7,33,504.6
Avg Vol (1M)15,06,457.95
Stock P/E97.63
Book Value₹652.39
Dividend Yield26%
ROE9.25%
ROA5.99%
Revenue (TTM)₹32,346 Cr
Revenue Growth9.4%
Profit Margin10.5%
Total Debt₹1,559 Cr
Shares Outstanding58 Cr
Face Value₹1
EPS (TTM)₹61.09
P/B2.37
Debt / Equity0.24
50 DMA₹1,509.75
200 DMA₹1,301.06
Day change-0.94%
Price Chart
₹1,533.9▲ 32.90% · 1Y
2025-07-172026-07-16
20-day avg volume: 15.1L shares
Pros
- Pays a dividend yield of 26.0%.
- Company is almost debt-free.
Cons
- Revenue fell 16% YoY.
- Stock trades at a high P/E of 98.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,567 Cr | ₹7,796 Cr | ₹7,979 Cr | ₹8,382 Cr | ₹7,868 Cr | ₹8,286 Cr | ₹8,646 Cr | ₹8,853 Cr |
| EBITDA | ₹1,436 Cr | ₹1,320 Cr | ₹1,317 Cr | ₹1,482 Cr | ₹1,303 Cr | ₹1,370 Cr | ₹1,496 Cr | ₹1,391 Cr |
| Net Profit | ₹919 Cr | ₹817 Cr | ₹846 Cr | ₹903 Cr | ₹825 Cr | ₹848 Cr | ₹910 Cr | ₹921 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹16,565 Cr | ₹19,719 Cr | ₹23,290 Cr | ₹25,155 Cr | ₹23,776 Cr | ₹25,146 Cr | ₹29,559 Cr | ₹32,346 Cr |
| EBITDA | ₹3,316 Cr | ₹3,439 Cr | ₹4,089 Cr | ₹4,659 Cr | ₹3,581 Cr | ₹2,765 Cr | ₹4,879 Cr | ₹5,555 Cr |
| Net Profit | ₹2,423 Cr | ₹2,365 Cr | ₹2,845 Cr | ₹5,335 Cr | ₹2,648 Cr | ₹1,928 Cr | ₹3,173 Cr | ₹3,486 Cr |
| EPS | 41.36 | 40.36 | 48.56 | 91.05 | 45.2 | 32.9 | 54.16 | 59.81 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹21,101 Cr | ₹26,454 Cr | ₹28,928 Cr | ₹33,854 Cr | ₹33,922 Cr | ₹39,890 Cr | ₹45,072 Cr | ₹49,785 Cr |
| Total Liabilities | ₹9,419 Cr | ₹12,562 Cr | ₹12,103 Cr | ₹11,925 Cr | ₹9,348 Cr | ₹13,038 Cr | ₹15,221 Cr | ₹17,138 Cr |
| Equity | ₹11,682 Cr | ₹13,892 Cr | ₹16,825 Cr | ₹21,929 Cr | ₹24,574 Cr | ₹26,852 Cr | ₹29,851 Cr | ₹32,647 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹2,653 Cr | ₹2,421 Cr | ₹5,142 Cr | ₹4,614 Cr | ₹6,275 Cr | ₹3,104 Cr | ₹4,201 Cr | ₹5,656 Cr |
| Investing | ₹-1,927 Cr | ₹-2,903 Cr | ₹-1,568 Cr | ₹599 Cr | ₹-3,212 Cr | ₹-3,978 Cr | ₹-4,256 Cr | ₹-1,876 Cr |
| Financing | ₹864 Cr | ₹1,919 Cr | ₹-1,947 Cr | ₹-1,365 Cr | ₹-2,969 Cr | ₹1,814 Cr | ₹800 Cr | ₹120 Cr |
| Free Cash Flow | ₹2,653 Cr | ₹2,421 Cr | ₹5,142 Cr | ₹4,614 Cr | ₹6,275 Cr | ₹3,104 Cr | ₹4,201 Cr | ₹5,656 Cr |
Shareholding
Promoter 51.82% Institutions 41.11% Public 7.08%
Efficiency & Working Capital
ROCE11.8%
Interest Coverage12.1
Dividend Payout—
Debtor Days66 d
Inventory Days121 d
Payable Days48 d
Cash Conversion Cycle139 d
Working Capital Days187 d
Shareholding Details
As of 2026-06-30
Promoter51.9%
FII16.4%
DII25.1%
Institutions41.5%
Public6.6%
Promoter Pledge13.8%
No. of Shareholders2,39,073
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.9% |
| FIIs | 22.5% | 20.7% | 18% | 16.7% | 16.6% | 16.3% | 15.3% | 14.4% | 14.2% | 13.9% | 15.2% | 16.4% |
| DIIs | 17.9% | 20.2% | 23.3% | 24.8% | 25.1% | 25.2% | 26.2% | 26.9% | 27.6% | 27.7% | 25.9% | 25.1% |
| Public | 7.8% | 7.2% | 6.9% | 6.7% | 6.5% | 6.7% | 6.6% | 6.9% | 6.4% | 6.6% | 7.1% | 6.6% |
| Promoter Pledge | 19.6% | 18.9% | 20.9% | 20.9% | 20.4% | 17.8% | 16.9% | 17.1% | 17.5% | 17.5% | 23.7% | 13.8% |
| No. of Shareholders | 2,59,638 | 2,41,944 | 2,44,575 | 2,38,622 | 2,48,488 | 2,57,962 | 2,69,323 | 2,72,208 | 2,47,662 | 2,36,859 | 2,41,298 | 2,39,073 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Rpr Sons Advisors Private Limited, Mrs.p.suneela Rani (jointly Holding) | Shareholding of Promoter and Promoter Group | 33.5% | 19.46 Cr |
| Quant Mutual Fund - Quant Arbitrage Fund | Public Shareholding | 5% | 2.89 Cr |
| K Nityananda Reddy | Shareholding of Promoter and Promoter Group | 4.4% | 2.54 Cr |
| Kirthi Reddy Kambam | Shareholding of Promoter and Promoter Group | 3.5% | 2.01 Cr |
| Hdfc Trustee Company Ltd. A/c Hdfc Balanced Advant | Public Shareholding | 3.2% | 1.86 Cr |
| Venkata Ramprasad Reddy Penaka | Shareholding of Promoter and Promoter Group | 3.1% | 1.78 Cr |
| Life Insurance Corporation Of India | Public Shareholding | 2.9% | 1.70 Cr |
| Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.ltd. (jointly Holding) | Shareholding of Promoter and Promoter Group | 2.9% | 1.66 Cr |
| M Sivakumaran | Shareholding of Promoter and Promoter Group | 2.5% | 1.44 Cr |
| Nps Trust- A/c Icici Prudential Pension Fund Schem | Public Shareholding | 2.3% | 1.36 Cr |
| Icici Prudential India Opportunities Fund | Public Shareholding | 2.1% | 1.21 Cr |
| Sbi Balanced Advantage Fund | Public Shareholding | 1.9% | 1.09 Cr |
| Kambam Spoorthi | Shareholding of Promoter and Promoter Group | 1.2% | 69,39,173 |
| K Rajeswari | Shareholding of Promoter and Promoter Group | 0.3% | 18,08,631 |
| M Sumanth Kumar Reddy | Shareholding of Promoter and Promoter Group | 0.3% | 15,85,214 |
| Trident Chemphar Limited | Shareholding of Promoter and Promoter Group | 0.1% | 7,82,241 |
| Axis Clinicals Limited | Shareholding of Promoter and Promoter Group | 0.1% | 6,51,920 |
| Prasada Reddy Kambham | Shareholding of Promoter and Promoter Group | 0.1% | 2,98,373 |
| Suneela Rani Penaka | Shareholding of Promoter and Promoter Group | 0% | 1,28,799 |
| K Suryaprakash Reddy | Shareholding of Promoter and Promoter Group | 0% | 7,380 |
| Penaka Neha Reddy | Shareholding of Promoter and Promoter Group | 0% | 0 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| M Sivakumaran | 0 | 0% | 2026-06-30 |
| Kottamanchi Rajeswari | 2,00,000 | 11.2% | 2026-06-30 |
| Suneela Rani Penaka | 0 | 0% | 2026-06-30 |
| Kambam Nithyananda Reddy | 96,50,000 | 38.4% | 2026-06-30 |
| Prasada Reddy Kambham | 1,00,000 | 33.8% | 2026-06-30 |
| Kambam Surya Prakash Reddy | 0 | 0% | 2026-06-30 |
| M Sumanth Kumar Reddy | 8,00,000 | 50.9% | 2026-06-30 |
| Kirthi Reddy Kambam | 27,00,000 | 13.6% | 2026-06-30 |
| Kambam Spoorthi | 4,00,000 | 5.8% | 2026-06-30 |
| Penaka Neha Reddy | 0 | 0% | 2026-06-30 |
| Trident Chemphar Limited | 0 | 0% | 2026-06-30 |
| Axis Clinicals Limited | 0 | 0% | 2026-06-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Kambam Nityananda Reddy | Vice Chairman & Managing Director | 2025 |
| M Madan Mohan Reddy | Whole-time Director | 2025 |
| P V Ramprasad Reddy | Non Executive Director | 2025 |
| Girish Paman Vanvari | Independent Director | 2025 |
| P Sarath Chandra Reddy | Non Executive Director | 2025 |
| Santanu Mukherjee | Independent Director | 2025 |
| M R Kumar | Chairman & Independent Director | 2025 |
| Satakarni Makkapati | Non Executive Director | 2025 |
| B Adi Reddy | Company Sec. & Compli. Officer | 2025 |
| Punita Kumar Sinha | Additional Director | 2025 |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 454 | 58 | 58 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| buyback | 2026-04-29 | ₹1475 max | — |
| dividend | 2025-08-08 | ₹4 (400%) | Interim |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 18,209 | 18 | 51 | 20 | 682 | 18,979 |
| 2025 | 8,213 | 0 | 14 | 0 | 0 | 8,227 |
| 2025 | 2,199 | 18 | 33 | 20 | 672 | 2,942 |
Insider / Designated-Person Trades
30 recent disclosure(s)
RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holdingRevoke · 1,16,35,862
RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holdingPledge · 1,67,00,000
A.Janardhana KamathDisposal · 6,000
Pavankumar PSDisposal · 1,000
Chandrasekhar Reddy KandatiDisposal · 2,000
RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holdingRevoke · 23,00,000
Substantial Acquisitions (SAST)
4 disclosure(s)
Market07/06/2024 · 2,00,000
Market24/11/2021 · 79,000
Inter-se Transfer / Gift30/09/2021 · 1,30,000
Inter-se Transfer / Gift30/09/2021 · 1,30,000
Company Information
Incorporated1986
ChairmanM R Kumar
AuditorDeloitte Haskins & Sells
Investor Email[email protected]; [email protected]
📍 Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search